Physician profile
Robert Wu
NPI 1790713824
$10,863.66
in general payments reported to CMS, 2019-2025
38 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $950 · 2021: $1,417 · 2022: $1,612 · 2023: $1,394 · 2024: $2,233 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,986.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,610.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,391.60 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $1,061.35 | 2020-2025 | |
| Lilly USA, LLC | $771.80 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $505.59 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $498.36 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $426.48 | 2022-2024 | |
| Merz North America, INC. | $415.98 | 2025 | |
| Medtronic, INC. | $324.07 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $303.43 | 2019-2022 | |
| Gilead Sciences, INC. | $288.21 | 2019-2025 | |
| Esperion Therapeutics, INC. | $267.86 | 2020-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.01 | 2023-2025 | Jardiance |
| Avanir Pharmaceuticals, INC. | $176.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.33 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.